NIKKEI 225
37,552.16 +113.55 (+0.30%) HANG SENG
16,793.27 +281.58 (+1.71%) CRUDE OIL
83.02 +0.17 (+0.21%) GOLD FUTURES
2,317.20 -29.20 (-1.24%) DOW
38,239.98 +253.58 (+0.67%) Bitcoin GBP
53,916.33 +146.32 (+0.27%)
Enlivex Therapeutics Ltd. (ENLV)
After hours:
| Previous close | 1.3200 |
| Open | 1.2400 |
| Bid | 1.2400 x 100 |
| Ask | 1.3300 x 100 |
| Day's range | 1.2400 - 1.3000 |
| 52-week range | 1.1500 - 4.5900 |
| Volume | |
| Avg. volume | 173,722 |
| Market cap | 23.62M |
| Beta (5Y monthly) | 1.05 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -1.4700 |
| Earnings date | 24 Apr 2024 - 07 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 7.00 |
GlobeNewswireEnlivex Announces Dosing of First Two Patients in its Randomized, Controlled Phase I/II Trial Evaluating Allocetra™ in Patients with Knee Osteoarthritis
Nes-Ziona, Israel, April 22, 2024 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, today announced that the first two patients have been dosed in the Company’s multi-country, randomized, controlled Phase I/II trial evaluating AllocetraTM in up to 160 patients with moderate to severe knee osteoarthritis. The Phase I/II multi-center trial is composed of two stages. The first stage is a safety run-in, open-
- GlobeNewswire
Enlivex Announces Authorization from the Danish Regulatory Agency for the Company’s Randomized, Controlled Phase I/II Trial Evaluating Allocetra in Patients with Knee Osteoarthritis
Nes-Ziona, Israel, April 16, 2024 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, today announced that the Danish Medicines Agency (DKMA) authorized the expansion into Denmark of the Company’s multi-country, randomized, controlled Phase I/II trial evaluating AllocetraTM in up to 160 patients with moderate to severe knee osteoarthritis. As previously announced, the Company received its first regulatory a
ZacksEnlivex (ENLV) Stock Plummets 51% in a Week: Here's Why
Enlivex (ENLV) plunges after it shares mixed results from a mid-stage study evaluating its lead drug as a potential treatment for sepsis.
